Latest Tremelimumab Stories
The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma.
A new study found that people with advanced melanoma who were treated with Bristol-Myers Squibb Co's Yervoy plus chemotherapy lived an average of two months longer than people who got chemotherapy alone.
CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by normalizing the immune response, today presented results from preclinical studies with 2F8, a murine analog of TRX518, a first-in-class immunomodulatory agent currently in a Phase 1 clinical study for the treatment of cancer.
The U.S. Food and Drug Administration today approved the use of ipilimumab for the treatment of previously treated metastatic melanoma.
NEW YORK, May 20 /PRNewswire-FirstCall/ -- Pfizer Oncology (NYSE: PFE) will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets.
PRINCETON, N.J., March 26 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that Dr. Geoffrey M.
Bristol-Myers Squibb Company and Medarex have announced updated survival data from three Phase II studies of ipilimumab in patients with advanced metastatic melanoma who had previously been treated.
Pfizer announced today that important study results involving the company's leading anticancer agent, SUTENT(R) (sunitinib malate), as well as data examining an investigational agent, CP-751,871, will be presented at the 33rd European Society for Medical Oncology (ESMO) Congress in Stockholm, 12--16 September 2008.
Oncolytics Biotech has announced that the US National Cancer Institute, part of the National Institutes of Health, has started enrollment in a Phase II clinical trial for patients with metastatic melanoma using systemic administration of Reolysin, Oncolytics's proprietary formulation of the human reovirus.
- A trick or prank.